Acasta Partners UK LLP
Sector Allocation
- Consumer Discretionary37.9%$84.5M
- Other30.1%$67.1M
- Materials19.8%$44.1M
- Energy5.7%$12.8M
- Real Estate3.9%$8.6M
- Healthcare2.7%$6.0M
AUM History
13fpro.ai/research/fund/acasta-partners-uk-llp-2090007
Conviction and streaks
Diversifying · top 10 = 94.7%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q3 2026
BABA
$84.5MLAR
$31.1M- JAZZ$28.4M
- McEwen$18.5M
- iShares$13.0M
METC
$12.6MOPI
$8.6M- Viridian$5.7M
HBM
$5.3MCELC
$3.6M- $2.4M
CCJ
$1.9M- Arrowhead$1.5M
USAR
$1.4MUEC
$1.3MISOU
$1.3MNXE
$1.2MBMM
$499KNFE
$183K
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/acasta-partners-uk-llp-2090007
Acasta Partners UK LLP 13F holdings — Q3 2026
$223.2M portfolio (+17.8% QoQ) · 19 holdings · Q3 2026 13F · top 10 are 95% of the stock portfolio
$84.5M
37.9% of stocks
-7%This quarter-9.5%Since filed4+ qtrsHeld$31.1M
13.9% of stocks
No changeThis quarter-25.5%Since filed4+ qtrsHeld- 3
JAZZ INVESTMENTS I LTD - CV BOND
$28.4M
12.7% of stocks
NewThis quarter—Since filedNew this quarterHeldAIQuality—Est. buy— - 4
McEwen Inc - CV BOND
$18.5M
8.3% of stocks
No changeThis quarter—Since filed—HeldAIQuality—Est. buy— - 5
iShares iBoxx $ High Yield Corporate Bond ETF - ORD
$13.0M
5.8% of stocks
-15%This quarter—Since filed—HeldAIQuality—Est. buy— $12.6M
5.7% of stocks
No changeThis quarter-13.6%Since filed4+ qtrsHeld$8.6M
3.9% of stocks
NewThis quarter-21.4%Since filedNew this quarterHeld- 8
Viridian Therapeutics, Inc. - CV BOND
$5.7M
2.6% of stocks
NewThis quarter—Since filedNew this quarterHeldAIQuality—Est. buy— $5.3M
2.4% of stocks
+76%This quarter-18.7%Since filed4+ qtrsHeldAIQualityAI quality score is Pro: unlock with a free trialEst. buyEstimated buy price is Pro: unlock with a free trialAdded 3 qtrs in a row$3.6M
1.6% of stocks
No changeThis quarter-10.6%Since filed4+ qtrsHeld
| # | Company | Value | Weight | This quarter | Since filed | Held | AI quality | Est. buy | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | $84.5M | 37.9% | -7% | -9.5% | 4+ qtrsTrimmed 2 qtrs in a row | — | Estimated buy price is Pro: unlock with a free trial | ||
| 2 | $31.1M | 13.9% | No change | -25.5% | 4+ qtrs | — | Estimated buy price is Pro: unlock with a free trial | ||
| 3 | JAZZ INVESTMENTS I LTD - CV BOND | $28.4M | 12.7% | New | — | New this quarter | — | — | |
| 4 | McEwen Inc - CV BOND | $18.5M | 8.3% | No change | — | — | — | — | |
| 5 | iShares iBoxx $ High Yield Corporate Bond ETF - ORD | $13.0M | 5.8% | -15% | — | — | — | — | |
| 6 | $12.6M | 5.7% | No change | -13.6% | 4+ qtrs | 18.3#2,768 | Estimated buy price is Pro: unlock with a free trial | ||
| 7 | $8.6M | 3.9% | New | -21.4% | New this quarter | — | Estimated buy price is Pro: unlock with a free trial | ||
| 8 | Viridian Therapeutics, Inc. - CV BOND | $5.7M | 2.6% | New | — | New this quarter | — | — | |
| 9 | $5.3M | 2.4% | +76% | -18.7% | 4+ qtrsAdded 3 qtrs in a row | AI quality score is Pro: unlock with a free trial | Estimated buy price is Pro: unlock with a free trial | ||
| 10 | $3.6M | 1.6% | No change | -10.6% | 4+ qtrs | — | Estimated buy price is Pro: unlock with a free trial |
All holdings — Acasta Partners UK LLP (Q3 2026)
19 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | Celcuity Inc.note | Healthcare | $2.4M | 1.1% | 2.50M | New | 4+ qtrs | — | 13F | |
| 12 | CAMECO CORP | Materials | $1.9M | 0.9% | 22K | — | 4+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | — | Arrowhead Pharmaceuticals, Inc. - CV BONDnote | — | $1.5M | 0.7% | 1.50M | — | — | — | 13F |
| 14 | USA Rare Earth, Inc. | Materials | $1.4M | 0.6% | 98K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | URANIUM ENERGY CORP | Materials | $1.3M | 0.6% | 143K | — | 4+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | IsoEnergy Ltd. | Materials | $1.3M | 0.6% | 151K | — | 3 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | NexGen Energy Ltd. | Materials | $1.2M | 0.5% | 132K | — | 4+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | Blue Moon Metals Inc. | Materials | $499K | 0.2% | 100K | -22% | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | New Fortress Energy Inc. | Energy | $183K | 0.1% | 29K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F |
What changed in Q3 2026
Against the previous quarter's 13F: 4 new, 1 added to, 3 trimmed, 3 sold out. Share-count changes; largest moves by dollar size first.
New positions (4)
Added to (1)
now $5.3M · held 4+ qtrs, 3 adds in a row
Trimmed (3)
Holdings by quarter
Every 13F Acasta Partners UK LLP has filed, 3 earlier quarters. Pick one to see what it held then.
Is it too late to follow Acasta Partners UK LLP?
Q3 2026 13F filed with the SEC on Oct 5, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of Acasta Partners UK LLP's top 20 holdings: 18/100 (our AI quality score, weighted by position size; 4 of the 20 are scored)
Top 10 since filing
-14.4%
Value-weighted move of the 10 largest stock positions
Turnover
6%
Last quarter
Top 10 weight
95%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
92%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 4 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2025 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
Acasta Partners UK LLP disclosed 19 positions worth $223.2M in its Form 13F-HR for Q3 2026, led by $BABA (Alibaba Group Holding Ltd) at 37.9% of the equity portfolio, followed by $LAR. During the quarter the fund opened 4 new positions and exited 3 and a full exit from $HIVE. The portfolio is most concentrated in Consumer Discretionary (37.9% of disclosed assets). All figures are sourced directly from Acasta Partners UK LLP’s Form 13F-HR filing with the SEC under CIK 2090007.
Funds like this
managers whose biggest positions overlap Acasta Partners UK LLP'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: Acasta Partners UK LLP
13F Pro is an AI hedge fund tracker and stock research platform. For Acasta Partners UK LLP (SEC CIK: 2090007), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Acasta Partners UK LLP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.